Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247919 · ClinicalTrials.gov registry record
DOAC ADRs Retrospective Study
A clinical trial, sponsored by Cipherome.
- Terminated
- Registry status
- 3
- Enrollment target
NCT04247919: Clinical Trial study, sponsored by Cipherome.
NCT04247919 is a clinical trial that was terminated before completion, run by Cipherome. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04247919 was terminated before completion, sponsored by Cipherome.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This retrospective study's objective is to evaluate if Cipherome's algorithm could have predicted the serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).
Primary Outcome
Reduction in hemoglobin of at least 2 g/dL Blood loss requiring transfusion of at least 2 units of whole blood or erythrocytes Critical anatomical sites of bleeding: intramuscular with compartment syndrome, intracranial, intraspinal, retroperitoneal, intraocular, pericardial, and atraumatic intra-articular bleeding. Bleeding led to death
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2020-07-24 |
Why NCT04247919 stopped before completion
NCT04247919 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04247919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04247919 about?
NCT04247919 is a clinical study titled "DOAC ADRs Retrospective Study". This retrospective study's objective is to evaluate if Cipherome's algorithm could have predicted the serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).
What is the current status of trial NCT04247919?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2020-01-10. Estimated completion is 2020-07-24.
Who is sponsoring clinical trial NCT04247919?
This trial is sponsored by Cipherome, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI